Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
Tetraphase Pharmaceuticals, Inc. (the Company) held its annual
meeting of stockholders on May31, 2017 (the Annual Meeting). At
the Annual Meeting, the Companys stockholders voted in the
following manner with respect to the following proposals:
| 1. |
The election of Directors as class I directors, each to serve for a three-year term expiring at the 2020 annual meeting of stockholders. The final voting results were as follows: |
| Nominee | For | Withheld | Non-Votes | |||||||||
|
L. Patrick Gage |
18,571,291 | 333,174 | 10,470,927 | |||||||||
|
Nancy Wysenski |
18,495,849 | 408,616 | 10,470,927 |
| 2. |
The ratification of the appointment of Ernst Young LLP as the Companys independent registered public accounting firm the current fiscal year ending December31, 2017 was approved as follows: |
|
For: |
29,287,372 | |||
|
Against: |
67,581 | |||
|
Abstain: |
20,439 |
| 3. |
The compensation of the Companys named executive officers was approved on an advisory basis as disclosed in the proxy statement for the 2017 Annual Meeting to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and narrative disclosure. The final voting results were as follows: |
|
For: |
18,080,503 | |||
|
Against: |
544,310 | |||
|
Abstain: |
279,652 | |||
|
Non Votes: |
10,470,927 |
About Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company’s TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Recent Trading Information
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) closed its last trading session up +0.47 at 7.65 with 427,653 shares trading hands.
